Research

Hormonal

Acute intravenous administration of the GLP-1 receptor agonist exenatide reduces brain activation in appetite- and reward-related regions (insula, amygdala, OFC, putamen) in response to food cues in obese and T2DM individuals, leading to reduced food intake, independent of metabolic/hormonal changes.

For obese or T2DM individuals, GLP-1 receptor agonists like exenatide reduce the brain's reward response to food cues, leading to lower food intake. This effect is driven by central nervous system mechanisms, not just metabolic changes or stomach emptying, and is mediated by GLP-1 receptors.

GoodSupportsHIGH confidence
Exenatide vs. placebo decreased food intake and food-related brain responses in T2DM patients and obese subjects (in insula, amygdala, putamen and orbitofrontal cortex). These effects were largely blocked by prior GLP-1 receptor blockade using exendin9-39.
Liselotte van Bloemendaal et al. · Diabetes · 2014

Why this rating

Randomized, placebo-controlled, crossover trial with rigorous controls (pancreatic-pituitary clamp) and fMRI validation.

Source

GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans

Liselotte van Bloemendaal et al. · Diabetes · 2014

DOI 10.2337/db14-0849

crossover · n=48Cited 405×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →